Loading stock data…
$0.94+0.01 (+1.08%)
Apimeds Pharmaceuticals US, Inc.
Apimeds Pharmaceuticals US, Inc. in the Healthcare sector is trading at $0.90 with a market capitalization of $20M. The stock is currently near its 52-week low of $0.79, remaining 93.1% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 30 is oversold, raising the odds of a near-term bounce. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$12.19M↓ | -$7.04M↓ | -$1.84M↑ | -$2.66M↓ | -$364,368 |
| Net Income | -$35.06M↓ | -$1.16M↑ | -$1.78M↑ | -$2.66M↓ | -$402,397 |
Apimeds Pharmaceuticals US, Inc. provides digital asset treasury solutions in bitcoin treasury infrastructure. The company is based in Ras al-Khaimah, the United Arab Emirates. Apimeds Pharmaceuticals US, Inc. operates as a subsidiary of Inscobee., I...